Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04657068 · ClinicalTrials.gov registry record · Phase 1
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
A Phase 1 study of Ovarian Cancer and Endometrial Cancer, sponsored by Artios Pharma.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 442
- Enrollment target
- 20
- Study locations
NCT04657068: Recruiting Phase 1 study of Ovarian Cancer and Endometrial Cancer, sponsored by Artios Pharma.
NCT04657068 is a Phase 1 study of Ovarian Cancer and Endometrial Cancer that is actively recruiting participants, run by Artios Pharma. The registered enrollment target is 442 participants, below the 727-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (39% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04657068, a Phase 1 study of Ovarian Cancer and Endometrial Cancer, is actively recruiting participants, sponsored by Artios Pharma.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 442 participants
- Enrollment target
- 20
- Study locations
Study Summary
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone and in combination with gemcitabine or irinotecan * Learn more about the side effects of ART0380 alone and in combination with gemcitabine or irinotecan * Learn more about the effectiveness of ART0380 alone and in combination with gemcitabine or irinotecan
Conditions Studied
Interventions
- DRUG Gemcitabine
- DRUG Irinotecan
- DRUG ART0380
Study Locations (20)
Florida
- Florida Cancer Specialists - Fort Myers
- Mayo Clinic (Florida) - Jacksonville
- Cancer Specialists of North Florida - Jacksonville
- Florida Cancer Specialists - Orlando
- Florida Cancer Specialists - Sarasota
- Florida Cancer Specialists - West Palm Beach
California
- USC Norris Comprehensive Cancer Center - Los Angeles
- Sansum Clinic - Santa Barbara
- Providence Medical Foundation - Santa Rosa
Colorado
- Rocky Mountain Cancer Center - Denver
- Sarah Cannon Research Institute at HealthONE - Denver
Minnesota
- Minnesota Oncology Hematology - Maple Grove
- Mayo Clinic (Minnesota) - Rochester
Alabama
- University of Alabama at Birmingham - Birmingham
Arizona
- Mayo Clinic (Arizona) - Scottsdale
Arkansas
- University of Arkansas - Winthrop P. Rockefeller Cancer Institute - Little Rock
Illinois
- Hope and Healing Cancer Services - Hinsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 442 participants |
| Start Date | 2021-01-27 |
| Est. Completion | 2027-12 |
| Phase | Phase 1 |
What NCT04657068 shows while recruiting
NCT04657068 is an interventional study that assigns participants to a tested intervention. The registered 442 participants enrollment target is mid-sized for trials with a published cap, below the 727-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (39% lower).
The record links to 9 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 3 interventions - of which Gemcitabine is the first listed.
NCT04657068 names 20 study sites across 11 states, led by Florida, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT04657068 about?
NCT04657068 is a clinical study titled "A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors". This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone and in combination with gemcitabine or irinotecan * Learn more...
What is the current status of trial NCT04657068?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 442 participants. The study started on 2021-01-27. Estimated completion is 2027-12.
What conditions does trial NCT04657068 study?
This clinical trial studies the following conditions: Ovarian Cancer, Endometrial Cancer, Advanced Cancer, Metastatic Cancer, Fallopian Tube Cancer.
What interventions are being tested in trial NCT04657068?
The interventions under investigation include: Gemcitabine (DRUG), Irinotecan (DRUG), ART0380 (DRUG).
Who is sponsoring clinical trial NCT04657068?
This trial is sponsored by Artios Pharma, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04657068 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04657068's enrollment target sits among peer trials
442 61st of 322 higher than 262 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03704766 · 442 participants · NA
Alpha-Defensin and Synovial Proteins to Improve Detection of Pediatric Septic Arthritis
- NCT05410145 · 442 participants · Phase 1
A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation
- NCT06659029 · 442 participants
Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users
- NCT06780670 · 443 participants · Phase 2
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI